EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

RRx-001 Accelerates Low Dose Oxaliplatin-Induced Cytotoxicity in Triple-Negative Breast Cancer Cells via Synergistic Antitumor Mechanisms

Rafid Kariem Al-Fatlawi, Wrood Salim Al-Khfajy

Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ) · 06.08.2026 · 11 (1) · 252-258

DOI: 10.54133/ajms.v11i1.3019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ), online erschienen am 06.08.2026. Verfasst von Rafid Kariem Al-Fatlawi und 1 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Triple-negative breast cancer (TNBC) represents an aggressive subtype that has few therapeutic options for targeting and is highly resistant to chemotherapy. The compound RRx-001 is a dinitroazetidine compound with both immune-modulating and epigenetic properties, whereas oxaliplatin elicits immunogenic cell death.

Objective

To evaluate the synergistic cytotoxic effects of RRx-001 combined with oxaliplatin in MDA-MB-231 TNBC cells.

Methods

Viability assays using the MTT assay were performed. The IC50 concentrations were derived from dose response curves. The drug interaction analysis was completed utilizing the Chou-Talalay method, along with CompuSyn software to calculate the combination index (CI) and dose reduction index (DRI). The intracellular reactive oxygen species (ROS) levels were assayed by performing a fluorometric assay with DCFH-DA.

Results

RRx-001 exhibited greater cytotoxicity (IC50=9.878 µM) than did oxaliplatin (IC50=202.2 µM). When the two drugs were used, the combination resulted in a significant decrease in the IC50 value for oxaliplatin (to 9.705 µM, ≈20.9-fold reduction). A strong synergy was seen (CI=0.0227 at Fa=0.05) with significant reductions in the doses required for each drug. Additionally, a combination of these two drugs significantly increases amounts of ROS compared to either drug alone.

Conclusions

RRx-001 has been shown to significantly enhance the cytotoxicity of oxaliplatin through synergistic and ROS-mediated pathways, suggesting that it may represent a viable option for a dose-sparing combinatorial therapeutic approach to treat TNBC.

Zitieren

APA

Al-Fatlawi, R. K., & Al-Khfajy, W. S. (2026). RRx-001 Accelerates Low Dose Oxaliplatin-Induced Cytotoxicity in Triple-Negative Breast Cancer Cells via Synergistic Antitumor Mechanisms. Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ), 11(1), 252-258. https://doi.org/10.54133/ajms.v11i1.3019

Vancouver

Al-Fatlawi RK, Al-Khfajy WS. RRx-001 Accelerates Low Dose Oxaliplatin-Induced Cytotoxicity in Triple-Negative Breast Cancer Cells via Synergistic Antitumor Mechanisms. Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ). 2026;11(1):252-258. doi:10.54133/ajms.v11i1.3019

BibTeX
@article{AlFatlawi2026,
  author = {Al-Fatlawi, Rafid Kariem and Al-Khfajy, Wrood Salim},
  title = {RRx-001 Accelerates Low Dose Oxaliplatin-Induced Cytotoxicity in Triple-Negative Breast Cancer Cells via Synergistic Antitumor Mechanisms},
  journal = {Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )},
  year = {2026},
  volume = {11},
  number = {1},
  pages = {252--258},
  doi = {10.54133/ajms.v11i1.3019}
}
Kostenlos starten →